“It’s about inequality, particularly income, racial and gender inequality,” de los Angeles said. “We’ve been raising these issues for quite some time, and we would like them to come out with meaningful proposals to address them, but our proposals have been met with deaf ears.”
The California Nurses Association, representing 14,000 nurses at UC’s six major medical centers and 10 student health centers, announced it will hold a sympathy strike Tuesday and Wednesday. The University Professional and Technical Employees, which represents social workers, pharmacists and physician assistants, also plans to walk out.
In all, 10,800 workers from the three unions are expected to walk off the job at UCSF. Statewide, about 25,000 AFSCME workers plan to strike. The total number could reach 53,000 with the addition of sympathy strikers.
Antrum said UCSF has rescheduled more than 300 surgeries and 800 cancer patient appointments at its Mission Bay and Parnassus Avenue campuses. All elective procedures have been delayed, and 1,900 replacement workers have been requested.
The UCSF emergency department on Parnassus and the ambulatory clinics for people with acute illnesses, such as the flu, will remain open. Patients with critical needs are being directed to affiliates, such as St. Mary’s in San Francisco and John Muir Medical Center in Walnut Creek, Antrum said.
For Gennifer Lendahl-Gonzales, it took a seemingly simple rose thorn to pierce her health and shatter her calm. While rare, her experience is a cautionary tale for anyone working outdoors. Randall BentonThe Sacramento Bee
The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann
Roche expects a U.S. Food and Drug Administration decision by Sept. 5. It has already announced some results of clinical trials that showed the cocktail boosted survival benefit for patients with metastatic non-squamous non-small cell lung cancer (NSCLC) compared to older treatments.
Tecentriq is approved to treat NSCLC after other therapies fail, but Roche is pushing to deploy its medicine with other drugs as early as possible to catch up to better-established immunotherapies from Merck and Bristol-Myers Squibb.
Merck’s Keytruda is approved for initial lung cancer treatment in some patients.
“We are working closely with the FDA to bring this treatment regimen to people with this type of lung cancer as soon as possible,” said Sandra Horning, Roche’s chief medical officer.
Tecentriq’s status as a late-comer in immunotherapy compared to Keytruda and Bristol-Myers Squibb’s Opdivo has contributed to sluggish sales.
In the first-quarter, Tecentriq revenue of 139 million Swiss francs (8.9 million) lagged the 154 million poll estimate in a Reuters poll and was just above the 132 million of the fourth quarter, which analysts cited as a blemish on results.
Still, Roche points to numerous ongoing studies in lung and other cancers that include Tecentriq, contending it still had a shot at beating rivals to market in first-line treatment of small cell and first-line squamous cell lung cancer.
The children competed in swimming first, then biked around the track that was marked by cones and chalk on the asphalt and then walked, with a variety of assisting equipment. Some did Olympic distances and others did iron man distances.
The triathlon at Domino's Farm in Ann Arbor was the brainchild of physical therapist Betsy Howell, who works at Mott's pediatric rehabilitation center.
Howell, a former triathlon competitor, got the idea for Sunday's event while competing last August at her first triathlon in 30 years.
"My goal was not to die and I didn't," Howell said. "But there was a group there called 'Team Triumph.' They pulled disabled kids in rafts, and they pulled them in a bike trailer, and then they push them in a jogger. I'm like 'that's really cool. That's awesome.'"